TY - JOUR
T1 - Experimental therapies in the treatment of cutaneous T-cell lymphoma
AU - Foss, F. M.
AU - Kuzel, T. M.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Although meaningful clinical responses have been demonstrated in cutaneous T-cell lymphoma using a number of therapeutic modalities, survival benefits have not been demonstrated for the majority of patients. Several novel therapies, including retinoids, purine analogs, biologic response modifiers, monoclonal antibodies, and fusion toxins have demonstrated activity and clinical promise in early studies.
AB - Although meaningful clinical responses have been demonstrated in cutaneous T-cell lymphoma using a number of therapeutic modalities, survival benefits have not been demonstrated for the majority of patients. Several novel therapies, including retinoids, purine analogs, biologic response modifiers, monoclonal antibodies, and fusion toxins have demonstrated activity and clinical promise in early studies.
UR - http://www.scopus.com/inward/record.url?scp=0029148488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029148488&partnerID=8YFLogxK
U2 - 10.1016/s0889-8588(18)30063-7
DO - 10.1016/s0889-8588(18)30063-7
M3 - Review article
C2 - 8522489
AN - SCOPUS:0029148488
VL - 9
SP - 1127
EP - 1137
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 5
ER -